Back to search results

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

This study, called AVAIL, aims to create a valuable resource for understanding and treating Non-Alcoholic Fatty Liver Disease (NAFLD). Researchers will collect liver tissue during standard liver biopsies, along with blood and urine samples, and conduct FibroScan (a non-invasive test to measure liver scarring and fat). This information will help scientists discover new treatments, identify people at higher risk for NAFLD, and develop more effective interventions. You may be eligible if you are 18 or older and are scheduled for a liver biopsy, or if you have a BMI of 25 or higher, with or without type 2 diabetes, and no NAFLD.

Study design
This is an observational study aiming to enroll 1250 participants. It is not testing a new treatment but rather collecting information to help future research.
What's involved
If you are in the biopsy group, you would provide additional liver tissue during your standard biopsy. All participants will have blood and urine collected, and a FibroScan performed.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is to create a biobank and registry at baseline. Longitudinal changes in liver fat and fibrosis will be evaluated with FibroScan, suggesting ongoing follow-up, but the duration is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04807868

AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)

Recruiting
Not specifiedAges 18+Observational
AdventHealth Translational Research Institute
~1,250 participants
Updated 2025-03-13 on ClinicalTrials.gov
What's tested:Standard of care liver biopsyFibroscanBiospecimen Collection

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical Metadata
Measured over Baseline

Conditions

Non-Alcoholic Fatty Liver Disease

Explore related trials

Nonalcoholic Fatty Liver Disease

NCT04807868

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AdventHealth Translational Research Institute

    Orlando, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Karen Corbin, PhD, RD · PRINCIPAL_INVESTIGATOR · Investigator

Who to contact

Recruitment Department
[email protected]
407-303-7100
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Females and Males ≥ 18 years of age.
Understands the procedures and agrees to participate by giving written informed consent.

Exclusion

Women who are pregnant when referred for a liver biopsy will be excluded.
Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.

What this trial measures

  • Creation of a Biobank of Liver Tissue Paired with a Registry of Histological and Clinical MetadataBaseline